You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Janssen disappointed with second NICE no for Spravato

Janssen says it is disappointed with second draft guidance from the National Institute for Health and Care Excellence (NICE) rejecting NHS funds for its nasal depression spray Spravato (esketamine).